← Back to Search

Other

N-acetylcysteine for Schizophrenia (NAC2 Trial)

Phase 4
Waitlist Available
Led By Yvonne Yang, MD, PhD
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 weeks (baseline), 4 weeks and 8 weeks of treatment with nac
Awards & highlights

NAC2 Trial Summary

This trial will help us understand whether NAC is a safe and effective treatment for schizophrenia.

Eligible Conditions
  • Schizophrenia
  • Cognitive Impairment

NAC2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 weeks (baseline), 4 weeks and 8 weeks of treatment with nac
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 weeks (baseline), 4 weeks and 8 weeks of treatment with nac for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Glutamate levels in prefrontal cortex
Glutathione levels in prefrontal cortex
Improvement of negative symptoms
Secondary outcome measures
Whole blood glutathione level
Other outcome measures
Cognitive Performance on the MCCB

NAC2 Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: N-acetylcysteineExperimental Treatment2 Interventions
Patients in this group will receive N-acetylcysteine (NAC) 1200mg orally twice daily (total daily dose 2400mg), for eight weeks. Each individual tablet contains 300mg NAC, therefore patients will take two tablets by mouth each morning and two tablets by mouth each evening. Manufacturer: Jarrow Industries, Inc.; Brand name: N-A-C Sustain
Group II: PlaceboPlacebo Group1 Intervention
Patients in this group will receive placebo tablets indistinguishable from NAC tablets, with the same protocol as NAC: two placebo tablets by mouth each morning, and two placebo tablets by mouth each evening. Manufacturer: Jarrow Industries, Inc.; Brand name: N-A-C Sustain
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cysteine
FDA approved

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,530 Previous Clinical Trials
10,278,151 Total Patients Enrolled
38 Trials studying Schizophrenia
4,839 Patients Enrolled for Schizophrenia
Yvonne Yang, MD, PhDPrincipal InvestigatorAssistant Clinical Professor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine
Yvonne S. Yang 2017. "Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02505477.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top